epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.
EPI-512, Phase III. Recruitment complete
Moderate to severe ulcerative colitis
WGB-512 induction against placebo in moderate to severe ulcerative colitis. Sponsor: Woodgrove Biologics (fictional), Immunology and GI.
When will this study finish recruiting? Set its sites yourself, or let the planner find the fewest per country that meet the deadline.
Study and plan
Woodgrove Biologics (fictional), Phase III, Immunology and GI. Month 0 is September 2021.
Randomise 471 (drop-out 15%) and screen about 906 (screen failure 48%)
Sep 2024
Confidence wanted
Sites per countryEdit the site counts in the table below
How much sites differSpread of site rates (coefficient of variation 0.9). Fitted trials range from 0.7 to 1.2.
Central finish (P50)Apr 2026month 55.2
Fast case (P10)Apr 2025month 43.9
Slow case (P90)Aug 2027month 71.4
Chance of meeting the deadline1%wanted 85%
Sites7010% likely to recruit nobody
Patients to screen906to randomise 471
Likely to finish in April 2026, 19 months after the deadline
EPI-512, patients randomised, cumulative by monthThe band holds 80% of 4,000 simulated studies; the coloured line is the central forecast; the line marked Actual is recruitment so far
Show data
Patients randomised by month: fast, central and slow cases of the simulation, and actual recruitment
Month
Fast case
Central
Slow case
Actual
Sep 2021
0
0
0
0
Mar 2022
2
1
0
1
Sep 2022
37
25
16
29
Mar 2023
110
80
57
79
Sep 2023
192
144
103
140
Mar 2024
277
207
150
192
Sep 2024
360
269
196
261
Mar 2025
443
333
242
316
Sep 2025
471
395
288
380
Mar 2026
471
458
336
448
Sep 2026
471
471
381
–
Mar 2027
471
471
427
–
Sep 2027
471
471
471
–
Mar 2028
471
471
471
–
Source: epiClinical Poisson-gamma simulation; actual recruitment to September 30th 2026. All data synthetic.
How likely is it to finish by a given month?
Almost no chance of finishing by September 2024
Finish month of 4,000 simulated studiesOne dot = 40 simulated studies · 1 of 100 dots finish in time
Drag the handle or
In time: 1%Median Apr 2026 · 1 dot not complete by Mar 2028Late: 99%
Source: epiClinical Poisson-gamma simulation
Show data
Chance that recruitment is complete by the end of each month
Month
Chance complete by then
Sep 2021
0%
Mar 2022
0%
Sep 2022
0%
Mar 2023
0%
Sep 2023
0%
Mar 2024
0%
Sep 2024
1%
Mar 2025
6%
Sep 2025
22%
Mar 2026
45%
Sep 2026
68%
Mar 2027
82%
Sep 2027
90%
Mar 2028
95%
Countries
Use
Country
Patients per site per month
Sites open between
Cap
Sites
Patients by finish
United States
0.113
Therapeutic area: 0.300 Immunology and GI baseline
Country: ×0.75 United States
Site type: ×0.988 Usual mix in United States
Track record: ×0.98 Expected mix for mostly repeat sites
Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
Patient acceptability: ×0.65 Placebo or no added treatment ×0.75, Blinded ×0.8
Competing trials: ×1 A few ×1
month 4.1 to 10.2
100
107
United Kingdom
0.127
Therapeutic area: 0.300 Immunology and GI baseline
Country: ×0.85 United Kingdom
Site type: ×0.975 Usual mix in United Kingdom
Track record: ×0.98 Expected mix for mostly repeat sites
Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
Patient acceptability: ×0.65 Placebo or no added treatment ×0.75, Blinded ×0.8
Competing trials: ×1 A few ×1
month 4.0 to 10.0
44
48
Spain
0.149
Therapeutic area: 0.300 Immunology and GI baseline
Country: ×1 Spain
Site type: ×0.977 Usual mix in Spain
Track record: ×0.98 Expected mix for mostly repeat sites
Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
Patient acceptability: ×0.65 Placebo or no added treatment ×0.75, Blinded ×0.8
Competing trials: ×1 A few ×1
month 7.6 to 13.6
71
65
Poland
0.220
Therapeutic area: 0.300 Immunology and GI baseline
Country: ×1.4 Poland
Site type: ×1.028 Usual mix in Poland
Track record: ×0.98 Expected mix for mostly repeat sites
Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
Patient acceptability: ×0.65 Placebo or no added treatment ×0.75, Blinded ×0.8
Competing trials: ×1 A few ×1
month 11.1 to 17.1
41
140
Turkey
0.148
Therapeutic area: 0.300 Immunology and GI baseline
Country: ×1 Turkey
Site type: ×0.965 Usual mix in Turkey
Track record: ×0.98 Expected mix for mostly repeat sites
Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
Patient acceptability: ×0.65 Placebo or no added treatment ×0.75, Blinded ×0.8
Competing trials: ×1 A few ×1
month 6.0 to 12.0
18
53
India
0.160
Therapeutic area: 0.300 Immunology and GI baseline
Country: ×1.1 India
Site type: ×0.952 Usual mix in India
Track record: ×0.98 Expected mix for mostly repeat sites
Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
Patient acceptability: ×0.65 Placebo or no added treatment ×0.75, Blinded ×0.8
Competing trials: ×1 A few ×1
month 6.0 to 12.0
15
58
Country risks to weigh when choosing sites
United States
Two sourced risks
All sites
The first US site opens quickly, but the rest of the US sites open slowly.
The US activates its first site quickly but scales its site fleet slowly · PM-03 · grade B
Tightens: site activation overdue
All sites
Under-represented groups need a plan from the start; diversity action plans apply to Phase III studies.
Racial and ethnic under-representation · PB-12 · grade A
United Kingdom
Two sourced risks
Some sites
Costing and contracting were the longest start-up step; the national contract has shortened it.
Fragmented, negotiated costing and contracting · POL-03 · grade A
If it recurs
The regulator's backlog of 2023 was cleared, but could recur.
Regulator assessment backlog · POL-02 · grade A
Spain
Two sourced risks
All sites
Site contracts took 117 days in 2016 and about 90 after national templates.
Fragmented, negotiated costing and contracting · POL-03 · grade A
All sites
Applications go through the EU Clinical Trials Regulation and its portal.
Regional regulatory transition friction (EU CTR and CTIS) · POL-15 · grade A
Poland
Two sourced risks
All sites
Applications go through the EU Clinical Trials Regulation and its portal.
Regional regulatory transition friction (EU CTR and CTIS) · POL-15 · grade A
All sites
A central ethics committee reviews every study; its effect on timelines is not measured.
Ethics-committee structure (random CPP allocation, 40 Italian territorial committees, a central Polish committee, Denmark's timeliness) · POL-20 · grade B
Turkey
Four sourced risks
All sites
Ethics committees fell from 145 to 49 in 2024, cutting review capacity.
Ethics-committee re-registration or re-constitution that cuts review capacity (India 2013; Turkey 2024) · RW-05 · grade B
Tightens: site activation overdue
All sites
A fixed pharmaceutical exchange rate has caused repeated medicine shortages.
Currency crisis with a fixed pharmaceutical exchange rate (Turkey 2018–2026) · RW-07 · grade D
Tightens: study drug at the site
All sites
Start-up time has not been measured since CRO data from 2014 and 2015.
Start-up time for India and Turkey is unmeasured · PM-04 · grade C
If it recurs
Sites in the south-east lie in the 2023 earthquake zone.
Major earthquake in a site region · SH-11 · grade C
India
Two sourced risks
All sites
Vulnerable participants in trials of new drugs need an audio-visual record of their consent.
Mandatory audio-visual consent for all participants · RW-03 · grade C
Tightens: consent findings
All sites
Start-up time is unmeasured beyond the statutory 90 working days.
Start-up time for India and Turkey is unmeasured · PM-04 · grade C
Tightens: site activation overdue
Risk-register entries; the choice of entries per country is epiClinical's.